News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

September 26, 2012

Conversion of Kyowa Hakko Kirin Korea Co., Ltd. into wholly owned subsidiary

Tokyo, Japan, September 26, 2012 --- Effective from September 21, 2012, Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") acquired a 10% stake in its subsidiary, Kyowa Hakko Kirin Korea Co., Ltd. ("Kyowa Hakko Kirin Korea"), having its business of development and sales of ethical drugs in Korea, from Jeil Pharmaceutical Co., Ltd. ("Jeil Pharmaceutical"), converting Kyowa Hakko Kirin Korea to a wholly owned subsidiary of Kyowa Hakko Kirin.

Kyowa Hakko Kirin aspires to become a global specialty pharmaceutical company, as group in one united body.

Summary of converting Kyowa Hakko Kirin Korea to wholly owned subsidiary
Date executed September 21, 2012
Contract parties (Seller) Jeil Pharmaceutical, (Buyer) Kyowa Hakko Kirin
Shares to be purchased 22,000 shares
Objective For efficient management in Korean pharmaceutical market
Company profile of Kyowa Hakko Kirin Korea
Established date May 24, 1991
Location 5F, Poonglim Bldg., 124, Teheran-ro, Gangnam-gu, Seoul 135-784, Korea
President & CEO Tae Se Kwon
Paid up capital 2.2 billion KRW
Shareholders Kyowa Hakko Kirin Co., Ltd. (100%)
Sales 43.4 billion KRW (2011)
Line of business Development and sale of ethical drugs in Korea
Main offices Head office: Seoul
Office: Busan, Daegu, Gwangiu, Daejeon, Gangwon


To Page Top